Quick Answer
Cadrenal Therapeutics, Inc. reported Research And Development Expense of $4.10 million for the year ending 2025.
- Cadrenal Therapeutics, Inc. showed a decrease of -2.5% in Research And Development Expense from 2024 to 2025.
- This data is from Cadrenal Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2022 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2022: $56.4 thousand | Q1 2023: $3.24 million | Q2 2023: $241.0 thousand | Q3 2023: $243.9 thousand | Q1 2024: $629.0 thousand | Q2 2024: $1.25 million | Q3 2024: $784.6 thousand | Q1 2025: $1.67 million | Q2 2025: $1.08 million | Q3 2025: $688.5 thousand.
- Over the full 5 years of available data (2022 to 2025), Cadrenal Therapeutics, Inc.'s Research And Development Expense has grown by 943.7%.
- Historical annual values: Fiscal year 2025: $4.10 million | Fiscal year 2024: $4.21 million | Fiscal year 2023: $4.08 million | Fiscal year 2023: $3.00 million | Fiscal year 2022: $392.9 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: